The role of insulin-like growth factors signaling in merlin-deficient human schwannomas

GLIA

Volumn 60, Issue 11, 2012, Pages 1721-1733

  Ammoun, Sylwia ^a   Schmid, M Caroline ^a   Ristic, Natalia ^a   Zhou, Lu ^a   Hilton, David ^a   Ercolano, Emanuela ^a   Carroll, Camille ^a   Hanemann, C Oliver ^a  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Human schwannoma; Insulin like growth factors; Proliferation adhesion survival

Indexed keywords

MERLIN; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GLYCOSYLATION; HUMAN; HUMAN CELL; NEURILEMOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CELL PROLIFERATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 84865860585     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22391     Document Type: Article

References (59)

1. Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA. 2010a. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 12: 834-843.
2. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. 2008. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68: 5236-5245.
3. Ammoun S, Hanemann CO. 2011. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 7: 392-399.
4. Ammoun S, Lindholm D, Wootz H, Akerman KE, Kukkonen JP. 2006. G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase. J Biol Chem 281: 834-842.
5. Ammoun S, Ristic N, Matthies C, Hilton DA, Hanemann CO. 2010b. Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. Neurobiol Dis 37: 141-146.
6. Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO. 2011. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol 13: 759-766.
7. Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM, Hanemann CO. 2012. Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene 31: 1710-1722.
8. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98: 13681-13686.
9. Carlberg M, Larsson O. 1996. Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts. Exp Cell Res 223: 142-148.
10. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
11. Du J, Sun C, Hu Z, Yang Y, Zhu Y, Zheng D, Gu L, Lu X. 2010. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS One 5: e15940.
12. Duan C. 2003. The chemotactic and mitogenic responses of vascular smooth muscle cells to insulin-like growth factor-I require the activation of ERK1/2. Mol Cell Endocrinol 206: 75-83.
13. Duggan SV, Lindstrom T, Iglesias T, Bennett PR, Mann GE, Bartlett SR. 2007. Role of atypical protein kinase C isozymes and NF-kappaB in IL-1beta-induced expression of cyclooxygenase-2 in human myometrial smooth muscle cells. J Cell Physiol 210: 637-643.
14. Fiedler J, Brill C, Blum WF, Brenner RE. 2006. IGF-I and IGF-II stimulate directed cell migration of bone-marrow-derived human mesenchymal progenitor cells. Biochem Biophys Res Commun 345: 1177-1183.
15. Flaiz C, Ammoun S, Biebl A, Hanemann CO. 2009a. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol 19: 27-38.
16. Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO. 2009b. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol 218: 137-144.
17. Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO. 2008. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. GLIA 56: 506-515.
18. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A. 2006. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 34: 1670-1679.
19. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. 2004. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242.
20. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M, Pao W. 2009. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4: e7273.
21. Hanemann CO, Bartelt-Kirbach B, Diebold R, Kampchen K, Langmesser S, Utermark T. 2006. Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol 32: 605-614.
22. Hanemann CO, Gabreels-Festen AA, Stoll G, Mueller HW. 1997. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): Normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs. Acta Neuropathol 94: 310-315.
23. Harding TC, Xue L, Bienemann A, Haywood D, Dickens M, Tolkovsky AM, Uney JB. 2001. Inhibition of JNK by overexpression of the JNL binding domain of JIP-1 prevents apoptosis in sympathetic neurons. J Biol Chem 276: 4531-4534.
24. Hebert E. 2006. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep 26: 7-17.
25. Hiromura M, Okada F, Obata T, Auguin D, Shibata T, Roumestand C, Noguchi M. 2004. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. J Biol Chem 279: 53407-53418.
26. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. 2003. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 12: 1211-1221.
27. Kim RJ, Kim SR, Roh KJ, Park SB, Park JR, Kang KS, Kong G, Tang B, Yang YA, Kohn EA, Wakefield LM, Nam JS. 2010. Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett 287: 172-181.
28. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R. 2010. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55: 67-75.
29. Korinthenberg R, Sauer M, Ketelsen UP, Hanemann CO, Stoll G, Graf M, Baborie A, Volk B, Wirth B, Rudnik-Schoeneborn S, Baborie A, Volk B, Wirth B, Rudnik-Schöneborn S, Zerres K. 1997. Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region. Ann Neurol 42: 364-368.
30. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, Eid JE, Greig G, Habben K, McCarthy CD, Gore L. 2010. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465.
31. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M. 2009. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28: 854-865.
32. Lee KH, Joung HA, Ahn JH, Kim KO, Oh IS, Shin YB, Kim MG, Kim DM. 2007. Real-time monitoring of cell-free protein synthesis on a surface plasmon resonance chip. Anal Biochem 366: 170-174.
33. Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, Giovannini M, Jacob A, Welling DB, Chang LS. 2009. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 45: 1709-1720.
34. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. 1995. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270: 26802-26806.
35. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG. 2010. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140: 477-490.
36. McClatchey AI, Fehon RG. 2009. Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 19: 198-206.
37. Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR. 1999. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci 19: 3847-3859.
38. Momcilovic M, Miljkovic Z, Popadic D, Markovic M, Savic E, Ramic Z, Miljkovic D, Mostarica-Stojkovic M. 2008. Methylprednisolone inhibits interleukin-17 and interferon-gamma expression by both naive and primed T cells. BMC Immunol 9: 47.
39. Morgan L, Jessen KR, Mirsky R. 1994. Negative regulation of the P0 gene in Schwann cells: Suppression of P0 mRNA and protein induction in cultured Schwann cells by FGF2 and TGF beta 1, TGF beta 2 and TGF beta 3. Development 120: 1399-1409.
40. Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, Oda H, Nakamura K, Tanaka S. 2004. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci 24: 6724-6732.
41. Ohshima-Hosoyama S, Hosoyama T, Nelon LD, Keller C. 2010. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Biochem Biophys Res Commun 399: 727-732.
42. Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, Mirsky R, Jessen KR. 2004. Krox-20 inhibits Jun-NH2-terminal kinase/c-Jun to control Schwann cell proliferation and death. J Cell Biol 164: 385-394.
43. Rexhepaj R, Rotte A, Pasham V, Gu S, Kempe DS, Lang F. 2010. PI3 kinase and PDK1 in the regulation of the electrogenic intestinal dipeptide transport. Cell Physiol Biochem 25: 715-722.
44. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO. 1998. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis 5: 55-64.
45. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 (see comments). Nature 363: 515-521.
46. Sakai H, Nishimura A, Watanabe Y, Nishizawa Y, Hashimoto Y, Chiba Y, Misawa M. 2010. Involvement of Src family kinase activation in angiotensin II-induced hyperresponsiveness of rat bronchial smooth muscle. Peptides 31: 2216-2221.
47. Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC. 2003. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology 144: 1984-1993.
48. Schumacher M, Jung-Testas I, Robel P, Baulieu EE. 1993. Insulin-like growth factor I: A mitogen for rat Schwann cells in the presence of elevated levels of cyclic AMP. Glia 8: 232-240.
49. Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, Larsson O. 2010. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3: ra10.
50. Shi YQ, Blattmann H, Crompton NE. 2001. Wortmannin selectively enhances radiation-induced apoptosis in proliferative but not quiescent cells. Int J Radiat Oncol Biol Phys 49: 421-425.
51. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F. 1991. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266: 15771-15781.
52. Utermark T, Alekov A, Lerche H, Abramowski V, Giovannini M, Hanemann CO. 2003a. Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells. Cancer 97: 1955-1962.
53. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO. 2005. Reduced apoptosis rates in human schwannomas. Brain Pathol 15: 17-22.
54. Utermark T, Kaempchen K, Hanemann CO. 2003b. Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol 13: 352-363.
55. Walsh PT, Smith LM, O'Connor R. 2002. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology 107: 461-471.
56. Wymann MP, Zvelebil M, Laffargue M. 2003. Phosphoinositide 3-kinase signalling-Which way to target? Trends Pharmacol Sci 24: 366-376.
57. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR. 2005. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25: 2384-2394.
58. Zhang M, Zhou Q, Liang QQ, Li CG, Holz JD, Tang D, Sheu TJ, Li TF, Shi Q, Wang YJ. 2009. IGF-1 regulation of type II collagen and MMP-13 expression in rat endplate chondrocytes via distinct signaling pathways. Osteoarthritis Cartilage 17: 100-106.
59. Zhao J, Guan JL. 2009. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 28: 35-49.